Ariad shares plunge after it pauses enrollment for leukemia drug trial

Ariad Pharmaceuticals (ARIA) collapses 59% after the company says that it's suspending the enrollment of new patients in trials for its Iclusig treatment for chronic myeloid leukemia.

The pause follows an increase in the rate of cardiac problems in patients who received Iclusig.

Pending FDA approval, Ariad hopes to resume enrollment with lower doses of the drug. Patients already on the medicine will continue to do so but with smaller doses.

The U.S. prescribing information for Iclusig remains unchanged. (PR)

From other sites
Comments (3)
  • Patent News
    , contributor
    Comments (1475) | Send Message
    9 Oct 2013, 07:41 AM Reply Like
  • loganj2
    , contributor
    Comments (44) | Send Message
    This should only be a temporary knee jerk reaction. Besides being an investor, I am also a patient and have been on the reduced dosage (15 mg) for over two years - my leukemia remains undetectable. Regrettably themarket reacts negatively to the company just doing due diligence and adjusting dosage after tracking patients. This is no different than any of the other kinase inhibitors that are on the market. I'm thinking about buying more because I strongly feel that the stock will rebund quickly once everypne figures out that the drug remains highly effective and that the dosage adjustment is just good medicine.
    9 Oct 2013, 11:53 AM Reply Like
  • goneskuba
    , contributor
    Comments (148) | Send Message
    I concur wholeheartedly. I beleive this is way too an over reaction to debt ceiling worries, recent data coming out basically blackballing the biotech industry as a whole, and of course over reaction to the news, which preliminarily placed it as a FDA stopped med altogether...then to be disclosed as such as above.


    This is a chemotx drug folks.....not a statin, cardio or DM drug, not ASA or blood thinner, not an MS med, not anti seizure med...etc


    We as Physicians realize when a black box warning on chemtox agents causing very well known side effects of all chemotx agents (liver and cardio toxicity).


    Do you know that an echocardiogram (actually MUGA) scan are needed prior to initation of chemotx, as is liver function tests.


    DVT/PE/VTE are also common in chemotx agents...but are also very common in cancer patients by themselves without need for iatrogenic causes.


    We are possibly looking at a drug that might actually provide cure in CML as they once touted with Gleevac. There has been, to my knowledge, no mutation caused by tx of Iclusig or any mutation that it didnt perform well against.


    It's a shame that Data from EPIC (thats what they used to call it) trial will be delayed as head to head against ZGleevac would really have bolstered this stock price, but instead we have the opposite effect from bad news.
    10 Oct 2013, 05:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs